BR112015025875A2 - formulações de combinação veterinária estável de lactonas macrocíclicas e imidazotiazóis - Google Patents

formulações de combinação veterinária estável de lactonas macrocíclicas e imidazotiazóis

Info

Publication number
BR112015025875A2
BR112015025875A2 BR112015025875A BR112015025875A BR112015025875A2 BR 112015025875 A2 BR112015025875 A2 BR 112015025875A2 BR 112015025875 A BR112015025875 A BR 112015025875A BR 112015025875 A BR112015025875 A BR 112015025875A BR 112015025875 A2 BR112015025875 A2 BR 112015025875A2
Authority
BR
Brazil
Prior art keywords
imidazothiazoles
combination formulations
macrocyclic lactones
stable
stable veterinary
Prior art date
Application number
BR112015025875A
Other languages
English (en)
Other versions
BR112015025875B1 (pt
Inventor
Francis De Rose Guy
Pundlik Kolhe Sachin
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50694063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015025875(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of BR112015025875A2 publication Critical patent/BR112015025875A2/pt
Publication of BR112015025875B1 publication Critical patent/BR112015025875B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

resumo “formulações de combinação veterinária estável de lactonas macrocíclicas e imidazotiazóis” a presente invenção é direcionada a composições estáveis compreenden-do no mínimo uma lactona macrocíclica ou seu derivado, combinada com levamisol e um agente estabilizante de amino açúcar, opcionalmente um agente antiparasitá-rio adicional, e um método para tratamento ou controle de uma infecção ou infesta-ção parasitária em um animal pela administração da citada composição.
BR112015025875-1A 2013-04-12 2014-04-10 Composição injetável estável para o tratamento de uma infecção endoparasitária por helmintos em animais não humanos, composição para o tratamento de uma infecção ou infestação endoparasitária por helmintos em um animal não humano, e uso de doramectina e levamisol, ou um sal farmaceuticamente aceitável do mesmo BR112015025875B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361811138P 2013-04-12 2013-04-12
US61/811,138 2013-04-12
PCT/US2014/033599 WO2014169092A1 (en) 2013-04-12 2014-04-10 Composition of macrocyclic lactones, levamisole, an amino sugar and an additional antiparasitic agent

Publications (2)

Publication Number Publication Date
BR112015025875A2 true BR112015025875A2 (pt) 2017-07-25
BR112015025875B1 BR112015025875B1 (pt) 2021-06-29

Family

ID=50694063

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025875-1A BR112015025875B1 (pt) 2013-04-12 2014-04-10 Composição injetável estável para o tratamento de uma infecção endoparasitária por helmintos em animais não humanos, composição para o tratamento de uma infecção ou infestação endoparasitária por helmintos em um animal não humano, e uso de doramectina e levamisol, ou um sal farmaceuticamente aceitável do mesmo

Country Status (11)

Country Link
US (1) US10307405B2 (pt)
EP (1) EP2983712B1 (pt)
BR (1) BR112015025875B1 (pt)
CL (1) CL2015002976A1 (pt)
CR (1) CR20150508A (pt)
ES (1) ES2846820T3 (pt)
MX (1) MX364170B (pt)
NZ (1) NZ712345A (pt)
PE (1) PE20151726A1 (pt)
PL (1) PL2983712T3 (pt)
WO (1) WO2014169092A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102017010598A2 (pt) * 2017-05-19 2018-12-04 Flavio Alves Da Rocha composições veterinárias de liberação retardada para controle de ovos e larvas de helmintos nas fezes dos ruminantes, uso das composições, uso de antelmínticos com essa finalidade
US11872208B2 (en) 2017-11-23 2024-01-16 Ceva Sante Animale Composition for treating parasites infestations
BR112021004218A2 (pt) * 2018-09-05 2021-05-18 Zoetis Services Llc composição veterinária de comprimido mastigável duro e palatável e uso da mesma para tratar ou prevenir uma infecção ou infestação parasitária em um animal
SI3815677T1 (sl) 2019-10-30 2023-12-29 Krka, D.D., Novo Mesto Stabilni veterinarski sestavek, ki obsega moksidektin in imidakloprid

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4144352A (en) 1977-12-19 1979-03-13 Merck & Co., Inc. Milbemycin compounds as anthelmintic agents
EP0165900A3 (de) 1984-06-08 1986-05-28 Ciba-Geigy Ag Neue Lactone, Verfahren zu ihrer Herstellung und ihre Verwendung in der Schädlingsbekämpfung
US4916154A (en) 1986-09-12 1990-04-10 American Cyanamid Company 23-Imino derivatives of LL-F28249 compounds
MXPA02010587A (es) 2000-04-27 2003-03-10 Sankyo Co Derivados de milbemicina 13-sustituidos, su preparacion y su uso contra insectos y otras plagas.
US7348417B2 (en) 2003-08-07 2008-03-25 Wyeth Method of purifying moxidectin through crystallization
US7671034B2 (en) * 2003-12-19 2010-03-02 Merial Limited Stabilized formulation of ivermectin feed premix with an extended shelf life
WO2006006021A2 (en) * 2004-06-28 2006-01-19 Glenmark Pharmaceuticals Limited Stabilized pharmaceutical compositions of preferably a statin
US20080125480A1 (en) * 2004-12-30 2008-05-29 Cheminova A/S Oil-In-Water Formulation Of Avermectins
US7840123B2 (en) * 2007-06-21 2010-11-23 S.C. Johnson & Son, Inc. Diffusion device
NZ585499A (en) 2007-11-26 2011-12-22 Merial Ltd Solvent systems for pour-on formulations for combating parasites
WO2010021555A1 (en) * 2008-08-18 2010-02-25 Schering-Plough Animal Health Limited Anthelmintic compositions
UA108641C2 (uk) * 2010-04-02 2015-05-25 Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
AU2011252987B2 (en) 2010-05-12 2013-05-02 Boehringer Ingelheim Animal Health USA Inc. Injectable parasiticidal formulations of levamisole and macrocyclic lactones
CA2857958C (en) * 2011-12-02 2020-08-25 Merial Limited Long-acting injectable moxidectin formulations and moxidectin crystal forms

Also Published As

Publication number Publication date
MX364170B (es) 2019-04-15
PE20151726A1 (es) 2015-11-18
CL2015002976A1 (es) 2016-05-06
EP2983712B1 (en) 2020-11-25
BR112015025875B1 (pt) 2021-06-29
ES2846820T3 (es) 2021-07-29
MX2015014310A (es) 2016-02-16
PL2983712T3 (pl) 2021-05-31
US20160051524A1 (en) 2016-02-25
NZ712345A (en) 2016-04-29
WO2014169092A1 (en) 2014-10-16
CR20150508A (es) 2015-11-18
EP2983712A1 (en) 2016-02-17
US10307405B2 (en) 2019-06-04

Similar Documents

Publication Publication Date Title
CL2018002920A1 (es) Nuevos derivados de pirazolopirimidina
CO2019004776A2 (es) Nuevos derivados de quinolina-3-carboxamida antihelmínticos
BR112017002221A2 (pt) 2-(morfolin-4-il)-1,7-naftiridinas
BR112015029144A2 (pt) formulações de gel para guiar radioterapia
CL2019003892A1 (es) Nuevos derivados de azaquinolina.
BR112015020823A8 (pt) 1-hidróxi-benzooxaboróis como agentes antiparasíticos, seus usos, e formulação".
CY1117209T1 (el) Συνθεσεις περιλαμβανοντας 15-ηερε και μεθοδοι χρησης των ιδιων
NZ704627A (en) Spirocyclic isoxazoline parasiticidal combinations
BR112015025875A2 (pt) formulações de combinação veterinária estável de lactonas macrocíclicas e imidazotiazóis
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
UY37971A (es) Derivados de indol macrocíclicos sustituidos
BR112017020975A2 (pt) combinações antelmínticas e seus usos
EA201690859A1 (ru) Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli
UY35848A (es) Tienopirimidinas
PH12021550338A1 (en) Palatable antiparasitic formulations
BR112016029888A2 (pt) composições parasiticidas compreendendo derivados de indol, métodos e usos dos mesmos
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
BR112017026834A2 (pt) composição compreendendo vitaminas b e vitaminas c e seu uso
UY37538A (es) Amidas aromáticas de ácidos carboxílicos
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
BR112015029260A2 (pt) derivados de tilosina e seu método de preparação
BR112013032567B1 (pt) composição aquosa antiparasitária veterinária solubilizada
BR112018070064A2 (pt) composições farmacêuticas estáveis para administração tópica e uso das mesmas
BR112014030287A2 (pt) composição farmacêutica

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ZOETIS SERVICES LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/04/2014, OBSERVADAS AS CONDICOES LEGAIS.